Pharmacotherapy: How well can we compare different biologic agents for RA?

Nature Reviews Rheumatology

Volumn 6, Issue 5, 2010, Pages 247-248

  Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK REDUCTION; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HUMANS; IMMUNOLOGIC FACTORS; META-ANALYSIS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 77951946750     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.58     Document Type: Short Survey

References (10)

1. The Cochrane Musculoskelet al. Group. What is a systematic review? [online], http://www.cochranemsk.org/cochrane/review/default. asp?s=1 (2010).
2. singh, J. A. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews, issue 4. Article no. : CD007848. doi:10.1002/14651858. CD007848. pub2 (2009).
3. Smolen, J. S., Aletaha, D., Koeller, M., weisman, M. & Emery, P. New therapies for treatment of rheumatoid arthritis. Lancet 370, 1861-1874 (2007).
4. van Vollenhoven, R. F. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial) : 1-year results of a randomised trial. Lancet 374, 459-466 (2009).
5. Emery, P. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann. Rheum. Dis. 61, 290-297 (2002).
6. Schoels, M. et al. Follow-up standards and treatment targets in rheumatoid arthritis (RA) : results of a questionnaire at the EULAR 2008. Ann. Rheum. Dis. 69, 631-637 (2010).
7. Luce, B. R. et al. Rethinking randomized clinical trials for comparative Effectiveness research: the need for transformational change. Ann. Intern. Med. 151, 206-209 (2009).
8. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann. Rheum. Dis. (in press).
9. Gaujoux-Viala, C. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. (in press).
10. Nam, J. L. et al. Current evidence for the management of rheumatoid arthritis with biological disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. (in press).